secwatch.observer — SEC 8-K summary
======================================

Issuer:     Milestone Pharmaceuticals Inc. (MIST)
CIK:        0001408443
Form:       8-K
Filed at:   2024-03-21T23:59:59+00:00
Accession:  0001104659-24-036941
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Milestone Pharma reports Q4 net loss of $13.6M; on track to resubmit NDA for etripamil in PSVT early Q2 2024
--------------------------------------------------------------------------------

- Net loss of $13.6M in Q4 2023, full year net loss $59.7M; Q4 revenue was $0 (vs $3.5M in Q4 2022).
- Cash and equivalents $66M as of Dec 31, 2023; March 2024 offering raised ~$32.4M net, extending cash runway into 2026.
- Plans to resubmit NDA for etripamil in PSVT early Q2 2024 after Type A meeting with FDA resolved RTF items.
- FDA reiterated guidance for AFib-RVR Phase 3 pathway contingent on PSVT NDA approval; End of Phase 2 meeting expected mid-2024.
- R&D expense fell to $5.5M in Q4 (vs $10.6M) as Phase 3 studies completed; commercial expense rose to $5.0M (vs $2.6M) for launch prep.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1408443/000110465924036941/0001104659-24-036941-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1408443/000110465924036941/tm249389d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-036941

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer